GlassScriptPhysician profile
Darren Eugene Geyer
NPI 1053311985
$7,032.49
in general payments reported to CMS, 2019-2025
34 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $982 · 2021: $806 · 2022: $876 · 2023: $1,282 · 2024: $976 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,300.68 | 2019-2025 | |
| Novo Nordisk INC | $1,293.63 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $567.67 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $549.84 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $542.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $413.24 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $269.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.82 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.78 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $165.46 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $153.81 | 2019 | |
| Gilead Sciences, INC. | $143.36 | 2019-2021 | |
| Amarin Pharma, INC. | $122.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $113.27 | 2022-2023 | |
| Dexcom, INC. | $96.99 | 2019-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $95.73 | 2019-2023 | Octrode |
| Bayer Healthcare Pharmaceuticals INC. | $71.97 | 2023-2024 | |
| Astellas Pharma US INC | $70.99 | 2019-2021 | |
| Genentech USA, INC. | $65.90 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $65.00 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.89 | 2019-2025 | Spravato |
| Mylan Specialty L.P. | $43.66 | 2020-2021 | |
| Corcept Therapeutics | $37.07 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $31.19 | 2025 | Zoryve |
| Allergan, INC. | $31.11 | 2020 | |
| Inspire Medical Systems, INC. | $30.89 | 2025 | Inspire |
| Sanofi Pasteur INC. | $27.58 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.09 | 2021 | |
| Halozyme INC | $21.40 | 2023 | |
| Medtronic, INC. | $18.19 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.47 | 2019 | |
| Radius Health, INC. | $15.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Geyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.